Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616001455459
Ethics application status
Approved
Date submitted
17/10/2016
Date registered
18/10/2016
Date last updated
21/09/2021
Date data sharing statement initially provided
18/03/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Open-label Extension Study of ZYN002 (transdermal gel) in Patients with Partial Onset Seizures
Query!
Scientific title
Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)
Query!
Secondary ID [1]
290306
0
Zynerba ZYN2-CL-004
Query!
Universal Trial Number (UTN)
nil
Query!
Trial acronym
STAR2
Query!
Linked study record
ACTRN12616000510448
Query!
Health condition
Health condition(s) or problem(s) studied:
Epilepsy
300561
0
Query!
Condition category
Condition code
Neurological
300414
300414
0
0
Query!
Epilepsy
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
ZYN002 will be administered as a transdermal gel for 24 months with all patients starting at ZYN002 - CBD 195 mg every 12 hours (390 mg daily), with the option after Month 1 to either increase or reduce the dose of ZYN002 as determined by the investigator. The dose may be increased to 292.5 mg every 12 hours (585 mg daily). After one month at the 585 mg daily dose, the Investigator has the option to increase the dose to 390 mg every 12 hours (780 mg daily).
After the Month 24 visit, or the last visit if the patient terminates early from the study, patients will have either a one week or two week taper period. Patients will have their dose reduced by 50% the first week and another 50% the second week and then treatment will be discontinued.
As applicable, ZYN002 gel will be applied to the skin of both the right and left shoulder and/or upper arms and right/left thighs.
Participants will bring used and unused sachets to each visit for site to check treatment compliance.
Query!
Intervention code [1]
296114
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
299857
0
To evaluate the long term safety and tolerability of ZYN002 in partial onset (focal) seizures in adult epilepsy patients over a 24-month treatment period. Assessed by: physical exams, neurological exams, examination of skin, vital signs, ECGs, clinical laboratory tests e.g. haematology, chemistry, urinalysis, pregnancy test (when applicable), assessing suicide risk and adverse event (AE) monitoring.
Query!
Assessment method [1]
299857
0
Query!
Timepoint [1]
299857
0
Safety and tolerability will be assessed at every study visit from Day 1 to End of study visit (Week 2 and Months 1, 2, 3, 6, 9, 12, 15, 18, 24, Adhoc visits and End of Study)
Query!
Secondary outcome [1]
328325
0
To evaluate the long term efficacy of ZYN002 in partial onset (focal) seizures in adult epilepsy patients over a 24-month treatment period. Assessed by: monitoring seizure frequency and type in daily diary.
Query!
Assessment method [1]
328325
0
Query!
Timepoint [1]
328325
0
Investigator will review daily diary at each study visit (Week 2 and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 and Adhoc visits).
Query!
Eligibility
Key inclusion criteria
1. Must have completed 12 weeks of the ZYN2-CL-03 protocol, with greater than 95% compliance with study drug application and daily seizure and skin check diaries.
2. Patient agrees to abide by all study restrictions and comply with all study procedures.
3. Patient must be adequately informed of the nature and risks of the study and give written informed consent on Day 1.
4. In the Investigator’s opinion, the patient is reliable and is willing and able to comply with all protocol requirements and procedures.
5. Females of child-bearing potential must have a negative urine pregnancy test at Day 1 and at Months 1, 2, 3, 6, 9, 12, 15, 18, 24, Adhoc and End of Study. Females of child-bearing potential and male patients with a partner of child-bearing potential must continue to use an acceptable method of contraception until at least 3 months after the last dose of study drug.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patient is receiving any investigational drugs or using any experimental devices.
2. Patient has an ongoing serious adverse event (SAE) or has experienced a SAE in ZYN3-CL-03 that in the opinion of the investigator should exclude them from participation.
3. Patient has been less than 95% compliant with study medication in ZYN2-CL-03.
4. Patient demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable as this is not a randomized trial
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
The safety and efficacy variables will be summarized descriptively for all patients in the open label extension study and also by the following dosing cohorts listed below which are based on the randomized treatment (total daily dose) received in the double-blind study (Placebo, ZYN002-195 mg, ZYN002-390 mg) and the initial treatment received (total daily dose) in the open-label extension study (ZYN002-390 mg). The dosing cohorts will be identified as: Placebo/390 mg, 195 mg/390 mg and 390 mg/390 mg, where the treatments are a double blind (DB) treatment dose (total daily dose)/initial open label treatment dose (total daily dose).
The pharmacokinetic variables for anti-epileptic drugs (AEDs) and CBD will be summarized descriptively for all patients in the open label extension study.
Additional dosing cohorts will be determined based on additional dose titrations that are occur during the open label trial.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/11/2016
Query!
Actual
3/11/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
4/07/2017
Query!
Date of last data collection
Anticipated
14/06/2019
Query!
Actual
31/08/2019
Query!
Sample size
Target
180
Query!
Accrual to date
Query!
Final
171
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
6806
0
Royal Melbourne Hospital - City campus - Parkville
Query!
Recruitment hospital [2]
6807
0
Austin Health - Austin Hospital - Heidelberg
Query!
Recruitment hospital [3]
6808
0
Prince of Wales Private Hospital - Randwick
Query!
Recruitment hospital [4]
6809
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [5]
6810
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [6]
6811
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [7]
6812
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [8]
6813
0
Monash Medical Centre - Clayton campus - Clayton
Query!
Recruitment hospital [9]
6814
0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Query!
Recruitment hospital [10]
6815
0
University of Sunshine Coast Health Clinics - Sippy Downs
Query!
Recruitment hospital [11]
9788
0
The Alfred - Prahran
Query!
Recruitment postcode(s) [1]
14471
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
14473
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
14472
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
18565
0
3004 - Prahran
Query!
Recruitment postcode(s) [5]
14469
0
3050 - Parkville
Query!
Recruitment postcode(s) [6]
14477
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
14470
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [8]
14476
0
3168 - Clayton
Query!
Recruitment postcode(s) [9]
14474
0
4029 - Herston
Query!
Recruitment postcode(s) [10]
14478
0
4556 - Sippy Downs
Query!
Recruitment postcode(s) [11]
14475
0
5042 - Bedford Park
Query!
Recruitment outside Australia
Country [1]
8306
0
New Zealand
Query!
State/province [1]
8306
0
Auckland, Wellington, Waikato and Christchurch
Query!
Funding & Sponsors
Funding source category [1]
294692
0
Commercial sector/Industry
Query!
Name [1]
294692
0
Zynerba Pharmaceuticals Inc.
Query!
Address [1]
294692
0
80 West Lancaster Avenue
Suite 300
Devon, PA 19333
Query!
Country [1]
294692
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Zynerba Pharmaceuticals Pty Ltd
Query!
Address
At the office of PriceWaterhouseCoopers, 2 Riverside Quay, Southbank VIC, 3006
Query!
Country
Australia
Query!
Secondary sponsor category [1]
293537
0
None
Query!
Name [1]
293537
0
Query!
Address [1]
293537
0
Query!
Country [1]
293537
0
Query!
Other collaborator category [1]
279265
0
Commercial sector/Industry
Query!
Name [1]
279265
0
Novotech (Australia) Pty Limited
Query!
Address [1]
279265
0
Level 3, 235 Pyrmont St
Pyrmont NSW 2009
Query!
Country [1]
279265
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
296116
0
Melbourne Health Human Research Ethics Committee
Query!
Ethics committee address [1]
296116
0
The Royal Melbourne Hospital Level 6 East 300 Grattan Street Parkville 3050 Victoria
Query!
Ethics committee country [1]
296116
0
Australia
Query!
Date submitted for ethics approval [1]
296116
0
28/09/2016
Query!
Approval date [1]
296116
0
25/10/2016
Query!
Ethics approval number [1]
296116
0
Query!
Summary
Brief summary
This study is an open-label extension study to Protocol ZYN2-CL-03 (STAR1). The study aims to evaluate the long term effectiveness, safety, tolerability and blood levels of twice daily ZYN002 in addition to regular seizure medication for 24 months in up to 180 adults with partial onset seizures (POS) who have participated in study ZYN2-CL-03. This will be done by analysing a daily seizure and skin irritation diary, drug levels in the blood at various times following drug administration, and side effects. Skin at the application sites will be checked to see if there is any irritation or reactions present after applications. Who is if for? You may be eligible to join this study if have completed the 12 weeks of study treatment on protocol ZYN2-CL-03. Study details: All participants will administer ZYN002 transdermal gel twice daily for 24 months. What does study participation involve? Eligible patients can immediately transition after completing day 84 (at Week 12) of the double-blind study, ZYN2-CL-03, to the open label study, ZYN2-CL-004. All participants in this extension study will receive active ZYN002. This could be the first time a participant receives ZYN002, depending on which treatment they received in the previous study (ZYN2-CL-03). After pre-dosing procedures are completed, patients will start study medication (Day 1). The first dose of study drug will be applied by the patient at this visit. Patients will be required to visit the clinic at Week 2 and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, Adhoc and End of Study to have study procedures completed. Participants will continue to record their seizure frequency and type in their daily diary. At the clinic visits the following procedures will occur: blood sampling; review of daily diary, medications, adverse events and skin irritation; measurement of blood pressure, heart rate, breathing rate and temperature ; suicide risk; and possibly, a brief physical and neurological exam, pregnancy tests (females only, if applicable) and an ECG. Participants withhold their morning application until after blood sample collection at these visits. Additional out-patient visits may be required if there is skin irritation present at the application site.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
69602
0
Prof Terence O’Brien
Query!
Address
69602
0
Alfred Health 55 Commercial Rd Melbourne VIC 3004
Query!
Country
69602
0
Australia
Query!
Phone
69602
0
+61 3 8344 5490
Query!
Fax
69602
0
+61 3 9347 1863
Query!
Email
69602
0
obrientj@unimelb.edu.au
Query!
Contact person for public queries
Name
69603
0
Carol O'Neill
Query!
Address
69603
0
Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue
Devon, PA 19333
Query!
Country
69603
0
United States of America
Query!
Phone
69603
0
+1 484 581 7481
Query!
Fax
69603
0
-
Query!
Email
69603
0
oneillc@zynerba.com
Query!
Contact person for scientific queries
Name
69604
0
Donna Gutterman
Query!
Address
69604
0
Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue
Devon, PA 19333
Query!
Country
69604
0
United States of America
Query!
Phone
69604
0
+1 484 581 7481
Query!
Fax
69604
0
-
Query!
Email
69604
0
guttermand@zynerba.com
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
confidential information
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy
2022
https://doi.org/10.1001/jamanetworkopen.2022.20189
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF